Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 15 Sanofi, Chilly-Mazarin, France. RATIONALE: Dupilumab, a human IL-4Ra mAb inhibiting IL-4 and IL-13, key drivers of type 2-mediated inflammation, is approved for uncontrolled moderate-to-severe atopic dermatitis in adults, and in the USA for patients aged > _12 years with moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma. In a phase 2a study, dupilumab improved endoscopic, radiologic, clinical, and patient-reported outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) patients. We report results from a phase 3 dupilumab study (SINUS-52;NCT02898454) in severe CRSwNP patients on daily intranasal mometasone furoate (MFNS). METHODS: Adults with CSRwNP previously treated with systemic corticosteroids (SCS) and/or NP surgery (n 5 448) were randomized 1:1:1 to subcutaneous dupilumab 300mg every 2 weeks (q2w) for 52 weeks, q2w for 24 weeks followed by every 4 weeks (q4w) for 28 weeks, or placebo q2w for 52 weeks. Outcomes included change from baseline in nasal polyp score (NPS), patient-reported nasal congestion (NC), CT Lund-Mackay (LMK), UPSIT smell test, SNOT-22 (Week 24/52), FEV 1 , and ACQ-6 scores (Week 24). RESULTS: Baseline disease characteristics were comparable between treatment groups. Dupilumab significantly (P<0.0001) improved NPS (-1.80/-2.40), NC (-0.87/-0.98), LMK (-5.13/-6.94), UPSIT (+10.52/ +10.30), and ) scores from baseline to Week 24/ 52 (LS-mean differences vs placebo). Dupilumab reduced SCS use/need for NP surgery (P<0.0001), and in comorbid asthma patients (59.6%) improved lung function (FEV 1 ;P<0.0001) and asthma control (ACQ-6;P<0.0001). The most common adverse event occurring at higher frequency in dupilumab vs placebo was injection-site reactions (q2w/q2w-q4w/placebo:14.8%/18.9%/13.3%). CONCLUSIONS: Add-on dupilumab to MFNS significantly improved endoscopic, radiologic, clinical, patient-reported sinonasal, and asthma outcomes in CRSwNP patients, and was well-tolerated.
L37 Pollen Food Allergy Syndrome (PFAS) Among Young Armenian Adults
Dr. Mariam R. Movsisyan, MD, Dr. Armine V. Hakobyan, Prof. Spartak S. Gambarov; Yerevan State Medical University, Yerevan, Armenia. RATIONALE: Food allergy is a significant global medical problem. From patient-based studies, it is known that food allergy in adults is often associated with hay fever. The Pollen Food Allergy Syndrome (PFAS) is a common form of food allergy, particularly in adults. PFAS usually occurs in people who are allergic to pollen from trees, grasses or weeds, but not all patients have seasonal allergy symptoms. The aim of our study was to evaluate the prevalence of PFAS in the young Armenian population and to identify the most common allergens causing PFAS. METHODS: A cross-sectional survey from November 2017 to September 2018 was conducted. Young adults from 18 to 24 years old were recruited from the general population. Interviews were conducted with 173 subjects, and skin prick testing was performed in those who mentioned symptoms of allergic rhinitis and food allergy. RESULTS: 59 cases of seasonal allergic rhinitis from 173 subjects were recorded. The number of cases of seasonal allergic rhinitis accompanied by food allergies was 22 (13 %). In most cases [16 (9.2 %)], the allergens which caused these reactions were fruits (such as strawberry, kiwi and apple) and vegetables (such as tomato and eggplant). Strawberry and tomato accounted for 6 (3.5 %) and 5 (3 %) of cases of PFAS, respectively. CONCLUSIONS: Pollen Food Allergy Syndrome (PFAS) is a common and potentially underdiagnosed condition in the Armenian population. The most common PFAS allergens in the Armenian population are strawberry and tomato.
